Results Snapshot
Figures in Cr
Standalone - Profit And Loss Results
Mar'26
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Profit And Loss Analysis Highlights
Net Sales
YoY Growth in year ended Mar 2026 is -0.54% vs 6.33% in Mar 2025
Operating Profit (PBDIT) excl Other Income
YoY Growth in year ended Mar 2026 is 2.93% vs 40.09% in Mar 2025
Interest
YoY Growth in year ended Mar 2026 is 63.64% vs -48.32% in Mar 2025
Profit After Tax
YoY Growth in year ended Mar 2026 is -7.65% vs 18.44% in Mar 2025
Compare Profit and Loss Results of Evonile Pharma
Figures in Cr
standalone - Profit And Loss Results
Change(INR)
Change(%)
No of Months
12
12
Operating Income
354.00
914.00
-560.00
-61.27%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
86.00
-86.00
-100.00%
Net Sales
354.00
827.00
-473.00
-57.19%
Expenditure (Ex Depriciation)
Stock Adjustments
-12.00
-11.00
-1.00
-9.09%
Raw Materials Consumed
210.00
265.00
-55.00
-20.75%
Power & Fuel Cost
0.00
29.00
-29.00
-100.00%
Employee Cost
21.00
96.00
-75.00
-78.12%
Operating Expenses
9.00
80.00
-71.00
-88.75%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
11.00
32.00
-21.00
-65.62%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
6.00
14.00
-8.00
-57.14%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
260.00
533.00
-273.00
-51.22%
Operating Profit (PBDIT) excl Other Income
94.00
294.00
-200.00
-68.03%
Other Income
38.00
11.00
27.00
245.45%
Operating Profit (PBDIT)
132.00
305.00
-173.00
-56.72%
Interest
1.00
1.00
0.00
0.00%
Profit before Depriciation and Tax
131.00
303.00
-172.00
-56.77%
Depreciation
1.00
28.00
-27.00
-96.43%
Profit Before Taxation & Exceptional Items
129.00
275.00
-146.00
-53.09%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
129.00
274.00
-145.00
-52.92%
Provision for Tax
36.00
65.00
-29.00
-44.62%
Profit After Tax
93.00
209.00
-116.00
-55.50%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
768.00
781.00
-13.00
-1.66%
Profit Available for appropriations
862.00
991.00
-129.00
-13.02%
Appropriations
862.00
991.00
-129.00
-13.02%
Equity Dividend (%)
500%
50%
450.00
Earnings Per Share
37.74
25.98
11.76
45.27%
Profit And Loss - Net Sales
Net Sales 354.33 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is -0.54% vs 6.33% in Mar 2025
Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 94.10 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is 2.93% vs 40.09% in Mar 2025
Profit And Loss - Interest
Interest 1.26 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is 63.64% vs -48.32% in Mar 2025
Profit And Loss - Profit After Tax
Profit After Tax 93.18 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is -7.65% vs 18.44% in Mar 2025